| Income Statement | 2025-06-30 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|
| Research and development | NaN | 12,922* | 14,424 | |
| General and administrative | NaN | 4,558* | 3,944 | |
| Total operating expenses | NaN | 17,480 | 18,368 | |
| Loss from operations | NaN | -17,480* | -18,368 | |
| Other income, net | NaN | 134* | 520 | |
| Net loss before income taxes | NaN | -17,346* | -17,848 | |
| Other segment expense | 218 | NaN | NaN | |
| Research and development-TIDAL-01 | -48 | NaN | NaN | |
| Research and development-Compensation | 406 | NaN | NaN | |
| Other income, net | 81 | NaN | NaN | |
| Provision for income taxes | 12 | NaN | NaN | |
| General and administrative | 5,388 | NaN | NaN | |
| Benefit (provision) for income taxes | NaN | 2,485* | -816 | |
| Depreciation expense | 31 | NaN | NaN | |
| Net loss | -5,490 | -19,831 | -17,032 | |
| Oci, debt securities, available-for-sale, gain (loss), before adjustment, after tax, total | NaN | NaN | 30 | |
| Net loss attributable to common stockholders, basic | NaN | -19,831 | NaN | |
| Comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest | NaN | NaN | -17,002 | |
| Net loss attributable to common stockholders, diluted | NaN | -19,831 | NaN | |
| Basic EPS | -0.24 | -0.861 | -0.74 | |
| Diluted EPS | -0.24 | -0.861 | -0.74 | |
| Basic Average Shares | 23,140,510 | 23,036,442 | 23,037,714 | |
| Diluted Average Shares | 23,140,510 | 23,036,442 | 23,037,714 | |
Turnstone Biologics Corp. (TSBX)
Turnstone Biologics Corp. (TSBX)